<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37075">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623881</url>
  </required_header>
  <id_info>
    <org_study_id>NCKH/CGRH_10_2015</org_study_id>
    <nct_id>NCT02623881</nct_id>
  </id_info>
  <brief_title>Cervical Pessary vs. Vaginal Progesterone for Preventing Premature Birth in IVF Twin Pregnancies</brief_title>
  <official_title>The Effectiveness of Cervical Pessary Versus Vaginal Progesterone for Preventing Premature Birth in IVF Twin Pregnancies: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vietnam National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mỹ Đức Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vietnam National University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effectiveness of cervical pessary (Arabin) and vaginal progesterone for
      preventing premature birth in twin pregnancies after IVF
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial.

      Women with twin pregnancies after IVF treatment, at 16-22 weeks of gestation, will be
      invited to participate into the study.

      Subjects meeting the study criteria will be randomized into two groups: (1) treated with
      cervical pessary (Arabin) or (2) treated with 400mg vaginal progesterone, once daily from
      16-22 weeks to 36 6/7 weeks.

      Sample size: 520 participants
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm birth before 34 weeks of gestation</measure>
    <time_frame>Up to 18 weeks from recruitment</time_frame>
    <description>Number of patients giving birth before 34 weeks of gestation divided by total number of patients per arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory distress syndrome</measure>
    <time_frame>Up to 24 weeks from recruitment</time_frame>
    <description>Number of babies with respiratory distress syndrome divided by total number babies born per arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotising enterocolitis</measure>
    <time_frame>Up to 24 weeks from recruitment</time_frame>
    <description>Number of babies with necrotising enterocolitis divided by total number babies born per arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mortality</measure>
    <time_frame>Up to 28 days after delivery</time_frame>
    <description>Number of neonatal dead divided by total number of live born babies per arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal discharge</measure>
    <time_frame>Up to 18 weeks from recruitment</time_frame>
    <description>Number of patients with complains for vaginal discharge divided to total number of women per arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Cervical pessary</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 33 6/7 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 33 6/7 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cervical pessary</intervention_name>
    <description>Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 33 6/7 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort</description>
    <arm_group_label>Cervical pessary</arm_group_label>
    <other_name>Arabin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal progesterone</intervention_name>
    <description>Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 33 6/7 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort</description>
    <arm_group_label>Vaginal Progesterone</arm_group_label>
    <other_name>Cyclogest 400mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for enrolment into this trial, each female subject must fulfil all of the
        following criteria at the start of enrolment, unless specified otherwise:

          -  Twin (mono- or dichorionic) pregnancy.

          -  Cervical length (measured at 16-22 weeks of gestation) &lt; 38 mm.

          -  Willing to participate in the study

        Exclusion Criteria:

        To be eligible for enrolment in this study each subject must not meet any of the following
        criteria:

          -  Cervical cerclage in place

             . Stillbirth or major congenital abnormalities in any of the baby

          -  Twin-twin transfusion syndrome

          -  Praevia placenta

          -  Severe vaginal discharge, Premature rupture of membranes

          -  Premature labor / Premature rupture of membrane

          -  Participate in another intervention trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuong M Ho, MD</last_name>
    <role>Study Director</role>
    <affiliation>Research Center for Genetics and Reproductive Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tuong M Ho, MD</last_name>
    <phone>+84 903633377</phone>
    <email>hmtuong@vnuhcm.edu.vn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anh H Dang, MSc.</last_name>
    <phone>+ 84 908302412</phone>
    <email>anh.dh@myduchospital.vn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>My Duc Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <state>Tan Binh District</state>
        <zip>70000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vinh Q Dang, MD.</last_name>
      <phone>+ 84 908225481</phone>
      <email>bsvinh.dq@myduchospital.vn</email>
    </contact>
    <contact_backup>
      <last_name>Linh K Nguyen, MD</last_name>
      <phone>+ 84 1263616880</phone>
      <email>bslinh.nk@myduchospital.vn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>December 3, 2015</lastchanged_date>
  <firstreceived_date>November 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vietnam National University</investigator_affiliation>
    <investigator_full_name>Manh Tuong Ho</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Cervical pessary</keyword>
  <keyword>Vaginal progesterone</keyword>
  <keyword>Twins</keyword>
  <keyword>Premature birth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
